- Home
- GOSS vs TDAC Comparison
GOSS vs TDAC Comparison
Compare GOSS & TDAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- TDAC
- Stock Information
- Founded
- GOSS 2015
- TDAC 2022
- Country
- GOSS United States
- TDAC United States
- Employees
- GOSS N/A
- TDAC N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- TDAC
- Sector
- GOSS Health Care
- TDAC
- Exchange
- GOSS Nasdaq
- TDAC NYSE
- Market Cap
- GOSS 203.3M
- TDAC 221.0M
- IPO Year
- GOSS 2019
- TDAC 2024
- Fundamental
- Price
- GOSS $1.16
- TDAC $10.19
- Analyst Decision
- GOSS Strong Buy
- TDAC
- Analyst Count
- GOSS 4
- TDAC 0
- Target Price
- GOSS $7.75
- TDAC N/A
- AVG Volume (30 Days)
- GOSS 1.6M
- TDAC 1.9K
- Earning Date
- GOSS 05-15-2025
- TDAC 01-01-0001
- Dividend Yield
- GOSS N/A
- TDAC N/A
- EPS Growth
- GOSS N/A
- TDAC N/A
- EPS
- GOSS N/A
- TDAC 0.16
- Revenue
- GOSS $124,590,000.00
- TDAC N/A
- Revenue This Year
- GOSS N/A
- TDAC N/A
- Revenue Next Year
- GOSS $190.37
- TDAC N/A
- P/E Ratio
- GOSS N/A
- TDAC $160.63
- Revenue Growth
- GOSS N/A
- TDAC N/A
- 52 Week Low
- GOSS $0.50
- TDAC $10.00
- 52 Week High
- GOSS $1.55
- TDAC $10.24
- Technical
- Relative Strength Index (RSI)
- GOSS 55.35
- TDAC N/A
- Support Level
- GOSS $1.09
- TDAC N/A
- Resistance Level
- GOSS $1.20
- TDAC N/A
- Average True Range (ATR)
- GOSS 0.09
- TDAC 0.00
- MACD
- GOSS 0.00
- TDAC 0.00
- Stochastic Oscillator
- GOSS 69.01
- TDAC 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About TDAC TRANSLATIONAL DEVELOPMENT ACQUISITI
Translational Development Acquisition Corp is a newly organized blank check company.